January 2014 Issue of MMM
January 2014 issue
In this issue's All-stars coverage you'll find five great industry success stories from the past year. Here, in a nutshell, is why each won
Click the above link to access the complete Digital Edition of the January 2014 issue, with all text, charts and pictures.
The skill, nimbleness and unflagging energy with which Amgen tackled some daunting challenges—plus a rich product pipeline and a surge in 2013 sales—made Amgen MM&M's ...
Intouch Solutions ended 2013 with about $70 million in revenue, and 465 employees—seven times the revenue and nearly five times the number of employees it ...
Despite a host of challengers, AbbVie has kept Humira atop the hotly competitive anti-TNF and broader autoimmune category
In a year when high hopes around several launches ended up fizzling, the hottest launch story belongs to biotech, with the debut of Biogen Idec's ...
In a year when goliath health portal competitors About.com, Yahoo Health and MSN Health are hemorrhaging visitors, Remedy Health Media is bucking the trend
Despite having the brightest data set of all the oral anticoagulants, the newest one is off to a rocky start. DTC advertising and medical education ...
With pharma transforming more rapidly than ever, seven industry vets chart a road map for meeting a changed industry's challenges. James Chase led the discussion.
Big Data is coming and with it the danger of pharmaceutical marketers relying on it too heavily
Big pharma marketers who've been complaining to Washington for decades about the unregulated nibbling at their market shares won historic relief when the Drug Quality ...
Although doctors still like sales reps, Capgemini and Quantia's researchers find their appeal is on the decline, while digital is on the rise. While age ...
Gilead will not add any more sales reps to Sovaldi despite the unanticipated indication it grabbed for genotype-1 patients
News on Araid Pharma, Bristol-Myers Squibb, Forest Labs and Eisai
Med Ed Report
Janssen's hepatitis C drug Olysio (simeprevir) offers modest benefit over standard of care, but resistance in a subgroup of patients could hinder broader uptake.
Nearly two dozen members of Congress signaled solidarity with 41 medical boards and 33 physician associations in opposing the inclusion of textbooks and reprints in ...
News on CME Coalition, Haymarket Medical Education, American Academy of Physician Assistants and Physicians Interactive
The company says Docnet is more than a social site—it's a hub that merges networking, research and financial (as in Sunshine) resources.
Six years after transitioning from a primary care/emergency physician focus to a strictly emergency medicine focus, Emergency Medicine has gotten an upgrade
News on PubMed, UBM Canon, F1000 Research and Elsevier
Unmet need has turned pharma toward specialty meds. Yet every success reduces unmet need, raising the bar. In this landscape, how do you ensure that ...
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
Chronic disease patients seek online support and information, and show little love for branded websites.
News on Nintendo, Pain.com, Leapfrog Group and Appthority
Famous from his reality show, "The Osbournes," Jack narrates his life with MS in a web documentary series.
AbbVie is firing on all of DTC's cylinders to educate and convert Crohn's Disease sufferers to Humira
Healthcare.gov's marketing efforts are getting some applause
IMS Health brought market access firm HGS Europe into the fold last month.
An organ-donation campaign with a Brazilian football tie-in, and a UK managed-access company's series of documentary films, took top honors.
The Boston-based agency hopes the new department will allow teams a broader perspective.
News on the Medical Advertising Hall of Fame, McCann WorldGroup, Allergan and Benchworks
It's fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes
A McKinsey Center for Government analysis shows that in the period 2001-2010, FDA approved 88% of NDAs and BLAs that were supported by advisory committees ...
Under a $4-million contract from FDA, RTI International researchers will look at consumers' responses to risk, benefit and cost information in direct-to-consumer prescription drug ads
Thoughtful PR counselors preach the virtues of ensuring a company's point of view be part of a negative story
Insights are often confused with findings and even worse, strategies. We have to know the difference
Well-conceived disease awareness communications can be a powerful vehicle in establishing an urgent, emotional connection with an audience
Jeff Winton, SVP, chief communications officer, Astellas
At Work With
LISA ADLER VP, corporate communications Millennium
Promotions and hires for manufacturers and agencies
There is room for growth, loyalty and long-term partnering
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.